Clinical Trial Detail

NCT ID NCT03583086
Title H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

thymic carcinoma

lung non-small cell carcinoma

Therapies

Nivolumab + Vorolanib

Age Groups: adult senior

No variant requirements are available.